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Letter 
Human leucocyte antigens (HLA) in 
neonates with an inadequate response to 
hepatitis B vaccination 
Inadequate responses to hepatitis B 
vaccine occur in approximately 5-15% 
of neonates. Factors that influence the 
response to vaccination include the 
immunogenetic state of the vaccine 
recipient: carriers of the human leucocyte 
antigen (HLA)-B8, DR3 do not develop 
adequate responses to hepatitis B 
vaccine 1. To determine the importance of 
the immunogenetic factor for the 
outcome of hepatitis B vaccination in 
neonates, we investigated the HLA type 
of infants with an inadequate r sponse to 
hepatitis B vaccination and analysed the 
subgroups non-infected low responders 
and infected non-responders for differ- 
ences in the specific HLA type. 
Between 1982 and 1991, 705 healthy 
newborns from HBsAg-positive mothers 
received HBIg at birth and were 
vaccinated within the first year with 
plasma or recombinant-DNA vaccine 
according to a three- or four-dose 
vaccination schedule 2. During the first 
year blood was assayed for HBsAg and 
anti-HBs (IU/1) at 3, 6, 11 and 12 months 
of age. Sixteen of the 705 newborns 
(2.3%) with anti-HBs titres < 10 IU/1 
were identified; eight infants with an 
anti-HBs level below 10IU/I and 
negative tests for HBsAg (non-infected 
low responders ) and another eight infants 
who became anti-HBs negative but 
HBsAg-positive (infected non-responders). 
HLA typing for class I and II antigens 
was performed, using standard micro- 
cytotoxicity test on peripheral blood 
mononuclear cells. 
Table 1 shows the HLA phenotypes of
the eight non-infected low responders and 
Tab le  1 HLA type for eight non-infected low responders and eight infected non-responders to 
hepatitis B vaccine 
Ethnic 
Group background a B 
HLA type 
DR 
Non-infected low responders 
1 Medit. 7 
2 Neth. 62 
3 Medit. 13 
4 Neth. 8 
5 Medit. 18 
6 Medit. 35 
7 Cap. V. 58 
8 Medit. 60 
Infected non-responders 
1 b Medit. 18 
2 b Medit. 18 
3 Medit. 49 
4 Medit. 35 
5 Medit. 35 
6 Asia 58 
7 Medit. 52 
8 Asia 55 
8 3 - 
18  3 
35 1 3 
56 1 3 
35 4 - 
53 11 
- 13 11 
72 13 15 
48 4 14 
48 4 14 
35 7 - 
37 11 
11 8 
15 13 
63 15 7 
61 11 13 
, Possibly homozygous 
aEthnic background: Mediterranean, The Netherlands, Cape Verde Islands, Asia. A 
of expected DR3 homozygotes in this ethnic group is 1 -2% 
blnfected non-responders 1 and 2 are brother and sister 
rough estimate 
the eight infected non-responders to 
hepatitis B vaccine. HLA-DR3 was 
present in four of the eight (50%; 95% 
CI: 15-85% )non-infected low responders 
and in none of the eight (0%) infected 
non-responders. Two non-infected low 
responders were probably homozygous 
for HLA-DR3. 
This study confirms that the HLA- 
DR3 haplotype plays a role in the low 
responsiveness to hepatitis B vaccination 
in non-infected neonates. In our study 
with only a small number of ethnically 
heterozygous individuals, all four DR3- 
positive children were non-infected low 
responders and two of them were 
probably homozygous for DR3. These 
low responders were not absolute 
non-responders, since all of them 
developed protective anti-HBs levels after 
hepatitis B revaccination i their second 
year of life 3. The two children homo- 
zygous for HLA-DR3 produced anti-HBs 
in the lowest range (45 and 55 IU/1, 
respectively) after revaccination in 
comparison to the other six revaccinated 
low responders (median 171, range 
49-3497IU/1). The observation that 
none of the eight non-responders, who 
became infected with hepatitis B virus, 
was DR3-positive suggests that HLA- 
associated low responsiveness i not 
causally related to this type of failure of 
hepatitis B vaccination. 
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